Cure My Disease

Don't miss your cure!

 Log in / Sign up

Retraining the senses to fight chemotherapy nerve damage

NCT ID NCT06724861

Symptom relief Sponsor: Assaf-Harofeh Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether a type of physical therapy called explicit sensory retraining can reduce nerve pain and improve balance in people who have chemotherapy-induced peripheral neuropathy (CIPN). Participants receive either three weekly sessions of sensory retraining for the legs and feet or usual care, then switch after a period. Researchers measure changes in neuropathy symptoms, pain, and mobility using standard tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Explicit sensory retraining for the lower extremities
What this could lead to
If it works, this could offer a drug-free way to reduce nerve pain and improve balance and mobility in people living with chemotherapy-induced peripheral neuropathy.
What could go wrong
This is a small early-stage trial with only 27 participants, so results may not apply broadly. The training involves only three sessions, which may be too brief to produce lasting change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CIPN by self-report (present or absent) \> 3 months after last chemotherapy treatment * age \> 18. Exclusion Criteria: * Pre-chemotherapy neuropathy/ sensory impairment * recurrent falls prior to chemotherapy (more than 2 per year) * CNS involvement * not ambulatory before chemotherapy * Hebrew proficiency not meeting questionnaires' needs.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age over 18 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age over 18 Chemotherapy-induced peripheral neuropathy Cipn - chemotherapy-induced peripheral neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shamir Medical center

    RECRUITING

    Tzrifin, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.